Roche's Genentech goes on deal spree, unveiling third deal on the same day
The business development executives at Roche’s Genentech have been busy shopping.
The company, founded in 2016 by Case Western Reserve University School of Medicine professors, has been enlisted to help Genentech develop medicines with neurological disorders such as multiple sclerosis. The Roche company already sells the intravenous therapy Ocrevus, which was approved for relapsing forms of multiple sclerosis as well as primary progressive multiple sclerosis in 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.